与使用抗抑郁药和抗精神病药相关的体重增加的风险因素、预防和治疗:最新临床综述。

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Expert Opinion on Drug Safety Pub Date : 2024-10-01 Epub Date: 2024-09-23 DOI:10.1080/14740338.2024.2396396
Marco Solmi, Alessandro Miola, Federico Capone, Simone Pallottino, Mikkel Højlund, Joseph Firth, Dan Siskind, Richard I G Holt, Olivier Corbeil, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, René Ernst Nielsen, Merete Nordentoft, Paolo Fusar-Poli, Catharina A Hartman, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Eduard Vieta, Heidi Taipale, Christoph U Correll
{"title":"与使用抗抑郁药和抗精神病药相关的体重增加的风险因素、预防和治疗:最新临床综述。","authors":"Marco Solmi, Alessandro Miola, Federico Capone, Simone Pallottino, Mikkel Højlund, Joseph Firth, Dan Siskind, Richard I G Holt, Olivier Corbeil, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, René Ernst Nielsen, Merete Nordentoft, Paolo Fusar-Poli, Catharina A Hartman, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Eduard Vieta, Heidi Taipale, Christoph U Correll","doi":"10.1080/14740338.2024.2396396","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.</p><p><strong>Areas covered: </strong>We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.</p><p><strong>Expert opinion: </strong>To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1249-1269"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review.\",\"authors\":\"Marco Solmi, Alessandro Miola, Federico Capone, Simone Pallottino, Mikkel Højlund, Joseph Firth, Dan Siskind, Richard I G Holt, Olivier Corbeil, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, René Ernst Nielsen, Merete Nordentoft, Paolo Fusar-Poli, Catharina A Hartman, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Eduard Vieta, Heidi Taipale, Christoph U Correll\",\"doi\":\"10.1080/14740338.2024.2396396\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.</p><p><strong>Areas covered: </strong>We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.</p><p><strong>Expert opinion: </strong>To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.</p>\",\"PeriodicalId\":12232,\"journal\":{\"name\":\"Expert Opinion on Drug Safety\",\"volume\":\" \",\"pages\":\"1249-1269\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14740338.2024.2396396\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2396396","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

导言严重精神疾病患者的心脏代谢健康状况较差。常用的抗抑郁药和抗精神病药经常会导致体重增加,这可能会进一步导致不良的心血管后果:我们检索了截至 2023 年 4 月的 MEDLINE,以了解与抗抑郁药/抗精神病药相关的体重增加的风险因素、预防和治疗策略方面的综述、(网络)荟萃分析、试验和队列研究。我们制定了 10 项临床建议:为预防、管理和治疗与抗抑郁药/精神药物相关的体重增加,我们建议 i) 在治疗前评估肥胖的风险因素;ii) 在基线和随访期间定期监测代谢健康状况;iii) 根据患者的偏好提供生活方式干预,包括定期锻炼和健康饮食,以优化患者的积极性;iv) 考虑对轻中度抑郁症和焦虑症患者进行一线心理治疗;v) 根据药物和患者体重增加的风险选择药物、viii) 尽可能改用对体重增加影响较小的抗精神病药物/抗抑郁药物; ix) 将早期体重增加作为进一步体重增加的预测指标,以确定干预/转换方案的时机、以及 x) 考虑在抗精神病药物中添加二甲双胍或胰高血糖素样肽-1 受体激动剂,或托吡酯(因可能对认知产生不良影响而属于二线用药),或阿立哌唑替代氯氮平或奥氮平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review.

Introduction: People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.

Areas covered: We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.

Expert opinion: To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
期刊最新文献
Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA adverse event reporting system. Pharmacovigilance insights into drug-induced cystitis: analysis of FDA data from 2004 to 2024. Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study. Mining and influencing factors analysis of sacituzumab govitecan adverse drug event based on FAERS database.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1